Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
JournalClinical Kidney Journal
PublisherOxford University Press
MetadataShow full item record
AbstractBackground: Hyperkalemia is a modifiable risk factor for sudden cardiac death, a leading cause of mortality in hemodialysis patients. The optimal treatment of hyperkalemia in hospitalized end stage renal disease (ESRD) patients is nonexsistent in literature which has prompted studies from outpatient dialysis to be extrapolated to inpatient care. The goal of this study was to determine if low potassium dialysate 1 meq/L is associated with higher mortality in hospitalized ESRD patients with severe hyperkalemia (serum potassium > 6.5 mmol/L). Methods: We conducted a retrospective study of all adult ESRD patients admitted with severe hyperkalemia between January 2011- August 2016. Results: There were 209 ESRD patients on hemodialysis admitted with severe hyperkalemia during the study period. Mean serum potassium was 7.1 mmol/L. In-hospital mortality or cardiac arrest in ESRD patients with severe hyperkalemia was 12.4%. Median time to dialysis after serum potassium result was 2.0 hours (25, 75 IQR 0.9, 4.2 hours). 47.4% of patients received dialysis with 1mEq/L concentration potassium bath. The use of 1mEq/L potassium bath was associated with significantly lower mortality or cardiac arrest in ESRD patients admitted with severe hyperkalemia (OR 0.27 95% C.I. 0.09-0.80, p = 0.01). Conclusion: We conclude that use of 1mEq/L potassium bath for treatment of severe hyperkalemia (>6.5 mmol/L) in hospitalized ESRD patients is associated with decreased in-hospital mortality or cardiac arrest.
Rights/Terms© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16141
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
- Authors: Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B
- Issue date: 2018 Sep
- Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
- Authors: Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Blais J, Li Q, Jardine MJ, Perkovic V, Wheeler DC
- Issue date: 2021 Jan
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
- Authors: Weir MR, Kline I, Xie J, Edwards R, Usiskin K
- Issue date: 2014 Sep
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
- Authors: Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, CANVAS Program Collaborative Group.
- Issue date: 2018 Jan 23
- Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
- Authors: Zhou Z, Jardine M, Perkovic V, Matthews DR, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Oh R, Simpson R, Watts NB, Neal B
- Issue date: 2019 Oct